Early treatment of systemic onset JIA with anakinra restores the IL-18 response

First line treatment with anakinra (an interleukin-1 (IL-1) receptor antagonist), results in a 'good' clinical response (ACRp90) in patients newly diagnosed with systemic onset juvenile idiopathic arthritis (SoJIA), and restores the deficient IL-18 response of natural killer (NK) cells, according to a new study.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news164034650.html">Early treatment of systemic onset JIA with anakinra restores the IL-18 response</a></p> <p>First line treatment with anakinra (an interleukin-1 (IL-1) receptor antagonist), results in a 'good' clinical response (ACRp90) in patients newly diagnosed with systemic onset juvenile idiopathic arthritis (SoJIA), and restores the deficient IL-18 response of natural killer (NK) cells, according to a new study.</p>